Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1D | O15297 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MIF | P14174 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17729167 | 0.86 | PPM1D (0.36) | PPM1DTDP1ALDH1A1POLBMIF | |
| SCHEMBL4925757 | 0.83 | PPM1D (0.43) | PPM1DTDP1ALDH1A1POLB | |
| SCHEMBL4925765 | 0.83 | PPM1D (0.43) | PPM1DTDP1ALDH1A1POLB | |
| SCHEMBL4925769 | 0.83 | PPM1D (0.43) | PPM1DTDP1ALDH1A1POLB | |
| SCHEMBL15541522 | 0.80 | PPM1D (0.41) | PPM1DALDH1A1POLBKMT2A | |
| SCHEMBL851434 | 0.79 | GAA (0.43) | TDP1ALDH1A1L3MBTL1POLBEPHX2 | |
| SCHEMBL20696426 | 0.78 | PPM1D (0.41) | PPM1D | |
| SCHEMBL1047978 | 0.77 | PPM1D (0.39) | PPM1D | |
| SCHEMBL21104119 | 0.76 | ALDH1A1 (0.39) | PPM1DTDP1ALDH1A1L3MBTL1POLB | |
| SCHEMBL20981656 | 0.76 | ALDH1A1 (0.39) | PPM1DTDP1ALDH1A1L3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756037-B1 | AMINO ALCOHOL DERIVATIVES AND THEIR ACTIVITY AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| US-7786307-B2 | suchas N-(4(S)-amino-5(S)-hydroxy-2(S)-isopropyl-6-piperidin-1-ylhexyl)-2-(3-methoxypropoxy)benzamide dihydrochloride, used for the treatment of hypertension, cardiovasculr disorders, complications owing to diabetes, vision deffects, hyperaldosteronism, states of anxiety and cognitive disorders | NOVARTIS AG (CH) | 2010-08-31 | — | — | US | disclosed |
| US-7767690-B2 | Amino alcohol derivatives and their use as renin inhibitor | NOVARTIS AG (CH) | 2010-08-03 | — | — | US | disclosed |
| EP-1735270-B1 | DIAMINO ALCOHOLS AND THEIR USE AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2010-06-30 | — | — | EP | disclosed |
| US-7718675-B2 | Diamino alcohols and their use as renin inhibitor | SPEEDEL EXPERIMENTA AG (CH) | 2010-05-18 | — | — | US | disclosed |
| US-20090118281-A1 | Amino Alcohol Derivatives And Their Use As Renin Inhibitor | NOVARTIS AG (CH) | 2009-05-07 | — | — | US | disclosed |
| US-20080058320-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-03-06 | — | — | US | disclosed |
| US-20070161622-A1 | 6-Phenyl-2-hydroxy-1,3-hexanediamine derivatives, e.g., 1-{3(S)-Amino-2(S)-hydroxy-5(S)-[4-methoxy-3-(3-methoxypropoxy)benzyl]-methylheptyl}piperidin-2-one hydrochloride; treating hypertension, heart failure, glaucoma, cardiac infarction, kidney failure and restenosis | SPEEDEL EXPERIMENTA AG (CH) | 2007-07-12 | — | — | US | disclosed |
| US-20070155743-A1 | Amino alcohol derivatives and their activity as renin inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-05 | — | — | US | disclosed |
| EP-1756037-A2 | AMINO ALCOHOL DERIVATIVES AND THEIR ACTIVITY AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| EP-1735270-A1 | DIAMINO ALCOHOLS AND THEIR USE AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2006-12-27 | — | — | EP | disclosed |
| EP-1725530-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-11-29 | — | — | EP | disclosed |
| EP-1711456-A2 | AMINO ALCOHOL DERIVATIVES AND THEIR USE AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005090304-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005070871-A2 | AMINO ALCOHOL DERIVATIVES AND THEIR ACTIVITY AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005070870-A2 | AMINO ALCOHOL DERIVATIVES AND THEIR USE AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005070877-A1 | DIAMINO ALCOHOLS AND THEIR USE AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118281-A1 | Amino Alcohol Derivatives And Their Use As Renin Inhibitor | REN, AGTR1, ADH1A | PPM1D 1656/4885TDP1 3730/4885ALDH1A1 161/4885 |
| US-20070155743-A1 | Amino alcohol derivatives and their activity as renin inhibitors | REN, AGTR1, AGTR2 | PPM1D 1225/4885TDP1 2872/4885ALDH1A1 244/4885 |
| US-20080058320-A1 | Organic Compounds | REN, AGTR1, ADH1C | PPM1D 2632/4885TDP1 2314/4885ALDH1A1 77/4885 |
| US-20070161622-A1 | 6-Phenyl-2-hydroxy-1,3-hexanediamine derivatives, e.g., 1-{3(S)-Amino-2(S)-hydroxy-5(S)-[4-methoxy-3-(3-methoxypropoxy)benzyl]-methylheptyl}piperidin-2-one hydrochloride; treating hypertension, heart failure, glaucoma, cardiac infarction, kidney failure and restenosis | REN, AGTR1, AGTR2 | PPM1D 795/4885TDP1 3352/4885ALDH1A1 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.